Hansa Biopharma AB certified as a Great Place to Work[® ]

11 Sep 2020, 08:00

Based on the results of a company-wide employee survey and a review of policies, Hansa Biopharma has been officially awarded the Great Place to Work certificate by the Great Place to Work Institute

Lund, Sweden September 11, 2020. Hansa Biopharma AB (“Hansa”), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its certification as a Great Place to Work 2020 by the independent institute Great Place to Work®, a global authority on workplace culture and leadership behaviour. The certification was primarily based on ratings provided by Hansa employees in an anonymous survey that assesses perspectives on leadership, organizational culture and trust.

“We are very happy and proud to be officially designated a Great Place to Work. Our mission - to develop innovative, lifesaving and life altering immunomodulating therapies, bring these to the patients with rare diseases who need them, and generate value to society at large - depends on our ability to attract, develop and retain the very best talent in the industry. This certification reflects our efforts to build a strong organization as we continue our growth trajectory and transition into a commercial-stage company”, says Søren Tulstrup, President & CEO of Hansa Biopharma.

Ninety-six percent of Hansa employees participated in the Great Place to Work survey. Great pride in joint achievements, team-spirit and managerial trust were identified as main strengths of the company.

About Great Place to Work®
Great Place to Work® is the global authority on workplace culture. Since 1992, they have surveyed more than 100 million employees around the world and used those deep insights to define what makes a great workplace: trust. Their unparalleled benchmark data is used to recognize Great Place to Work-Certified™ companies and the Best Workplaces™ in more than 60 countries, including the 100 Best Companies to Work For® and World's Best list published annually in Fortune. Everything they do is driven by the mission to build a better world by helping every organization become a Great Place to Work For All™. To learn more, visit greatplacetowork.com.

Files

Release

For further information, please contact:
Anne Säfström Lanner
Chief Human Resources Officer
Hansa Biopharma
M: +46 (0) 709–298 133
E:anne.safstromlanner@hansabiopharma.com

Katja Margell
Head of Corporate Communications
Hansa Biopharma
Mobile: +46 (0) 768-198 326
E-mail: katja.margell@hansabiopharma.com

About Hansa Biopharma
Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, gene therapy and cancer. The Company’s lead product candidate, imlifidase, is an antibody cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. Imlifidase has been granted conditional approval in the European Union for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Commercial launch in select European countries is expected in the fourth quarter of 2020. Hansa’s research and development program is advancing the Company’s enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases, gene therapy and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in other European countries and in the U.S.